Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF-R1/R2 Peptide Vaccine in Advanced Solid Tumors
NCT01949688Phase 2Completed
- Sponsor
- Shiga University
- Start
- Jun 2010
- Primary completion
- Mar 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vegfr1 + vegfr2 peptide vaccine in solid tumor (2 arms), sponsored by Shiga University. Primary endpoints: Number of adverse events of vaccination therapy at 2 months and Overall Survival at 2 months. Started Jun 2010; status: completed.
02
Drugs
vegfr1 + vegfr2 peptide vaccine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01949688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949688.